SLS vs. NXTC, ASMB, MEIP, ENLV, NRXP, MBIO, CARM, SNSE, NBRV, and ASLN
Should you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include NextCure (NXTC), Assembly Biosciences (ASMB), MEI Pharma (MEIP), Enlivex Therapeutics (ENLV), NRx Pharmaceuticals (NRXP), Mustang Bio (MBIO), Carisma Therapeutics (CARM), Sensei Biotherapeutics (SNSE), Nabriva Therapeutics (NBRV), and ASLAN Pharmaceuticals (ASLN). These companies are all part of the "pharmaceutical preparations" industry.
SELLAS Life Sciences Group vs.
SELLAS Life Sciences Group (NASDAQ:SLS) and NextCure (NASDAQ:NXTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.
SELLAS Life Sciences Group has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500. Comparatively, NextCure has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500.
10.7% of SELLAS Life Sciences Group shares are owned by institutional investors. Comparatively, 54.7% of NextCure shares are owned by institutional investors. 1.6% of SELLAS Life Sciences Group shares are owned by insiders. Comparatively, 11.9% of NextCure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, SELLAS Life Sciences Group and SELLAS Life Sciences Group both had 1 articles in the media. SELLAS Life Sciences Group's average media sentiment score of 1.87 beat NextCure's score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.
NextCure received 62 more outperform votes than SELLAS Life Sciences Group when rated by MarketBeat users. Likewise, 61.40% of users gave NextCure an outperform vote while only 53.33% of users gave SELLAS Life Sciences Group an outperform vote.
NextCure's return on equity of -40.05% beat SELLAS Life Sciences Group's return on equity.
SELLAS Life Sciences Group presently has a consensus price target of $7.00, indicating a potential upside of 326.83%. NextCure has a consensus price target of $7.00, indicating a potential upside of 321.69%. Given SELLAS Life Sciences Group's stronger consensus rating and higher possible upside, equities analysts clearly believe SELLAS Life Sciences Group is more favorable than NextCure.
SELLAS Life Sciences Group has higher earnings, but lower revenue than NextCure. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than NextCure, indicating that it is currently the more affordable of the two stocks.
Summary
NextCure beats SELLAS Life Sciences Group on 9 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SELLAS Life Sciences Group Competitors List
Related Companies and Tools
